We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+22.82%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$354M
AUM Growth
-$79.9M
Cap. Flow
-$200M
Cap. Flow %
-56.47%
Top 10 Hldgs %
85.92%
Holding
20
New
1
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$9.38M
2
LPCN icon
Lipocine
LPCN
+$4.38M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$88.1M
2
DYAX
DYAX CORPORATION
DYAX
+$16.8M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.6M
4
TXMD icon
TherapeuticsMD
TXMD
+$5.12M

Sector Composition

Rank Sector Weight
1 Healthcare 60.64%
2 Miscellaneous 39.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAC
1
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$91.2M 25.74%
1,178,474
– –
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$38.3M 10.81%
311,853
– –
HRTX icon
3
Heron Therapeutics
HRTX
$63M
$34.1M 9.63%
1,095,734
– –
CHRS icon
4
Coherus Oncology
CHRS
$226M
$25.2M 7.09%
870,269
– –
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$22.5M 6.33%
138,274
– –
LRMR icon
6
Larimar Therapeutics
LRMR
$421M
$18.8M 5.29%
45,123
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.4B
$14.1M 3.97%
811,152
– –
ORKA
8
Oruka Therapeutics
ORKA
$6.39B
$12.4M 3.5%
+7,136
New +$9.38M
LPCN icon
9
Lipocine
LPCN
$18.4M
$10.9M 3.07%
74,701
+35,294
+90% +$4.38M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$10.6M 2.99%
500,000
– –
ARCT icon
11
Arcturus Therapeutics
ARCT
$460M
$9.81M 2.77%
214,286
– –
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.52B
$5.58M 1.57%
373,686
-1,370,670
-79% -$15.6M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$5.31M 1.5%
451,400
– –
ZSPH
14
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$5.24M 1.48%
100,000
– –
JUNO
15
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.81M 1.36%
90,206
-1,659,793
-95% -$88.1M
OCRX
16
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.67M 0.75%
703,730
– –
TXMD icon
17
TherapeuticsMD
TXMD
$25.7M
– –
-16,930
Closed -$5.12M
DYAX
18
DELISTED
DYAX CORPORATION
DYAX
– –
-1,000,659
Closed -$16.8M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q2 2015 Portfolio in Review

As of Q2 2015, VHCP Management held 20 positions worth $354M, down 18% from $434M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management withdrew a net $200M in Q2 2015, closing 2 positions and reducing 3 holdings. Its most notable exit was DYAX CORPORATION, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 71% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in Oruka Therapeutics worth $12.4M.

  • VHCP Management's largest Q2 2015 buy was Oruka Therapeutics: 7,136 shares worth $12.4M.
  • VHCP Management added most to Lipocine in Q2 2015, an estimated $4.38M increase.
  • VHCP Management's biggest Q2 2015 reduction was Juno Therapeutics, Inc., cutting an estimated $88.1M.
  • VHCP Management fully exited DYAX CORPORATION in Q2 2015, selling an estimated $16.8M.
  • VHCP Management's ten largest holdings make up 86% of its $354M portfolio in Q2 2015.
  • VHCP Management opened 1 new position and closed 2 in Q2 2015.
  • VHCP Management's portfolio value fell 18% quarter-over-quarter to $354M.

Based on VHCP Management's 13F filing for Q2 2015, filed 13 Aug 2015.